Last reviewed · How we verify

Tildrakizumab Prefilled Syringe

Brigham and Women's Hospital · FDA-approved active Small molecule

Tildrakizumab Prefilled Syringe is a IL-23 inhibitor (monoclonal antibody) Small molecule drug developed by Brigham and Women's Hospital. It is currently FDA-approved for Moderate to severe plaque psoriasis.

Tildrakizumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) to reduce inflammatory immune responses in the skin.

Tildrakizumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) to reduce inflammatory immune responses in the skin. Used for Moderate to severe plaque psoriasis.

At a glance

Generic nameTildrakizumab Prefilled Syringe
SponsorBrigham and Women's Hospital
Drug classIL-23 inhibitor (monoclonal antibody)
TargetIL-23 (interleukin-23), p19 subunit
ModalitySmall molecule
Therapeutic areaImmunology / Dermatology
PhaseFDA-approved

Mechanism of action

Tildrakizumab binds to the p19 subunit of IL-23, a key cytokine involved in the pathogenesis of psoriasis and other inflammatory skin conditions. By inhibiting IL-23 signaling, it suppresses the differentiation and activation of pathogenic T cells, particularly Th17 cells, thereby reducing skin inflammation and improving clinical outcomes in psoriasis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tildrakizumab Prefilled Syringe

What is Tildrakizumab Prefilled Syringe?

Tildrakizumab Prefilled Syringe is a IL-23 inhibitor (monoclonal antibody) drug developed by Brigham and Women's Hospital, indicated for Moderate to severe plaque psoriasis.

How does Tildrakizumab Prefilled Syringe work?

Tildrakizumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) to reduce inflammatory immune responses in the skin.

What is Tildrakizumab Prefilled Syringe used for?

Tildrakizumab Prefilled Syringe is indicated for Moderate to severe plaque psoriasis.

Who makes Tildrakizumab Prefilled Syringe?

Tildrakizumab Prefilled Syringe is developed and marketed by Brigham and Women's Hospital (see full Brigham and Women's Hospital pipeline at /company/brigham-and-women-s-hospital).

What drug class is Tildrakizumab Prefilled Syringe in?

Tildrakizumab Prefilled Syringe belongs to the IL-23 inhibitor (monoclonal antibody) class. See all IL-23 inhibitor (monoclonal antibody) drugs at /class/il-23-inhibitor-monoclonal-antibody.

What development phase is Tildrakizumab Prefilled Syringe in?

Tildrakizumab Prefilled Syringe is FDA-approved (marketed).

What are the side effects of Tildrakizumab Prefilled Syringe?

Common side effects of Tildrakizumab Prefilled Syringe include Nasopharyngitis, Upper respiratory tract infection, Injection site reactions, Headache.

What does Tildrakizumab Prefilled Syringe target?

Tildrakizumab Prefilled Syringe targets IL-23 (interleukin-23), p19 subunit and is a IL-23 inhibitor (monoclonal antibody).

Related